Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?

Saved in:
Bibliographic Details
Title: Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?
Authors: O'Meara TA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Burstein HJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: Hal_burstein@dfci.harvard.edu.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Feb; Vol. 37 (2), pp. 133-135. Date of Electronic Publication: 2025 Oct 17.
Publication Type: Editorial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2025.10.012